Skip to content
Home/Companies/Biotech/Focal Biosciences
Focal Biosciences

Focal Biosciences

Biotech·Switzerland·Active·4yr hold
Entry
2022
Hold
4yr
Status
Active

Who owns Focal Biosciences?

Focal Biosciences is a Swiss Biotech company, currently owned by Apollo Health Ventures since 2022.

Hand-verified · updated 2026-07-07

Open JSON · CC-BY
Apollo Health Ventures
Investor
Apollo Health Ventures
Apollo Health Ventures Fund II · 2021 · Life Sciences VC

Key facts

HQSwitzerland
SectorBiotech
StatusActive
Websitefocalbiosciences.com

More from Apollo Health Ventures Fund II

Other portfolio companies in the same fund.

BioNYRA Pharma
Active
BiotechFrance· 2026
Cognito Therapeutics
Active
United States· 2026
Scripta Therapeutics
Active
BiotechUnited Kingdom· 2025
Therini Bio
Therini Bio
Active
BiotechUS· 2025
Booster Therapeutics
Active
BiotechGermany· 2024
Auron Therapeutics
Auron Therapeutics
Active
BiotechUS· 2022

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Focal Biosciences?

Focal Biosciences is currently owned by Apollo Health Ventures, through Apollo Health Ventures Fund II, since 2022.

When did Apollo Health Ventures acquire Focal Biosciences?

Apollo Health Ventures acquired Focal Biosciences in 2022.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue